曲美布汀、谷维素联合嗜酸乳杆菌治疗肠易激综合征的研究

Research of the clinical effect of trimebutine and oryzanol as a treatment on patients with irritable bowel syndrome

目的:探讨马来酸曲美布汀胶囊、谷维素联合复方嗜酸乳杆菌治疗肠易激综合征的临床疗效。方法:选择120例肠易激综合征患者,分为治疗组60例和对照组60例。治疗组给予马来酸曲美布汀胶囊、谷维素及复方嗜酸乳杆菌三联治疗,对照组予马来酸曲美布汀胶囊及谷维素治疗。结果:治疗组的总有效率为86.67%,对照组的总有效率为71.67%,两组疗效比较差异有统计学意义(P<0.05)。结论:马来酸曲美布汀胶囊、谷维素联合复方嗜酸乳杆菌片治疗肠易激综合征,疗效显著,依从性良好,不良反应少,明显优于马来酸曲美布汀胶囊单联合谷维素治疗IBS,值得临床推广和应用。

Objective To observe the clinical effect of trimebutine maleate capsules, oryzanol joint Compound Eosinophil -Lactobacillus tablets treating the patients with irritable bowel syndrome. Methods 120 eases of irritable bowel syndrome,60 cases in the treatment group ,60 eases in the control group. The treatment group received trimebutine maleate,oryzanol and Compound Eosinophil -Lactobaeillus, the control group only received trimebutine maleate and oryzanol . Results The total effective rate of the treatment group was 86. 67% and control group was 71.67% ,the total effective rate of the two groups were statistically significant differences in their efficacy （P 〈 0. 05 ）. Conelusion Trimebutine maleate capsules, oryzanol joint compound Lactobacillus acidophilus tablets in the treatment of IBS have a signifi- cant effect, with better compliance and fewer side effects. It is significantly better than trimebutine maleate capsules single joint oryzanol treatment, and it is worth to promote and apply.